1. Methodology and confidence framework

This tracker covers active US pediatric MSO PE platforms across five sub-segments: pediatric primary care, pediatric urgent care, pediatric subspecialty plus hospital-based ED and anesthesia, pediatric home services, and pediatric adjacent (ASCs, value-based care, therapy, autism multidisciplinary). Coverage window: January 1, 2024 through June 20, 2026. Each platform cell carries a per-cell confidence rating (HIGH, MEDIUM, LOW, or GAP) based on the degree of primary-source verification. HIGH means the sponsor identity, entry date, and transaction structure are confirmed in either sponsor press release, target company press release, SEC filing, or court docket. MEDIUM means the headline fact is reported in trade press (Healthcare Levin, Behavioral Health Business, HIT Consultant, PR Newswire, Business Wire) but at least one element (stake size, precise date, exit timing) remains unconfirmed. LOW means trade press references are second-hand or stale. GAP means a fact circulated in pediatric M&A pipeline chatter that we could not verify in primary sources; we explicitly flag these rather than smooth them over.

Primary sources used include: Pediatrix Medical Group SEC filings (10-Q, 8-K) (https://www.stocktitan.net/sec-filings/MD/10-q-pediatrix-medical-group-inc-quarterly-earnings-report-6cea3be90e86.html); sponsor press releases from Apollo, TPG, Great Hill Partners, Webster Equity Partners, M33 Growth, Centerbridge, Blackstone, Bain Capital, and Welsh Carson Anderson & Stowe; Federal Trade Commission press releases and court filings (S.D. Tex. and N.D. Cal.); Bureau of Labor Statistics Occupational Employment and Wage Statistics May 2025 release (https://www.bls.gov/oes/current/oes_stru.htm); CMS Federal Register entries; American Academy of Pediatrics workforce data (https://www.aap.org/en/get-involved/aap-committees/committee-on-pediatric-workforce/); American Board of Pediatrics workforce data (https://www.abp.org/content/data-and-workforce); National Resident Matching Program annual results (https://www.nrmp.org/wp-content/uploads/2025/05/Main_Match_Results_and_Data_20250529_FINAL.pdf); HRSA Pediatric Specialty Loan Repayment Program funding letters (https://bhw.hrsa.gov/funding/apply-loan-repayment/pediatric-specialty-lrp); KFF Medicaid and CHIP tracker (https://www.kff.org/medicaid/medicaid-and-chip-eligibility-enrollment-and-renewal-policies-as-states-resume-routine-operations-following-the-unwinding-of-the-pandemic-era-continuous-enrollment-provision/); CDC MMWR Vaccines for Children entries (https://www.cdc.gov/mmwr/volumes/74/wr/mm7437a2.htm); FOCUS Investment Banking pediatrics valuation update (https://focusbankers.com/pediatrics-practice-valuation/); Sofer Advisors 2025-2026 multiples guide (https://soferadvisors.com/insights/blog/medical-practice-valuation-multiples-2025-2026-complete-guide/); Mertz Taggart Q4 2025 behavioral health M&A report (https://www.mertztaggart.com/post/q4-2025-behavioral-health-m-a-report); Private Equity Stakeholder Project healthcare deals review (https://pestakeholder.org/reports/pe-healthcare-deals-2025-in-review/); Crunchbase and PitchBook funding histories (https://pitchbook.com/profiles/company/61436-71). All cited URLs were last verified on June 20, 2026.

Two methodology guardrails warrant explicit statement. First, Mertz Taggart does not publish a dedicated pediatric quarterly; the firm’s published cadence covers behavioral health, home-based care, and post-acute. The pediatric multiples bands in Section 14 are triangulated from FOCUS Investment Banking, Sofer Advisors, Scope Research, and Provident Healthcare Partners commentary, not from a Mertz Taggart pediatric series. We use Mertz Taggart only for adjacent behavioral health and home-based care comparators where the firm does publish (HIGH confidence). Second, several commonly-cited pediatric platforms are physician-owned or family-office-adjacent rather than institutional PE-controlled. We do not infer PE sponsorship from rumor; we flag absence of confirmation as LOW or GAP rather than promote chatter into the active platform table.

2. Macro spine: pediatric workforce, wages, and Medicaid trajectory

The American Academy of Pediatrics counts more than 67,000 pediatricians, pediatric medical subspecialists, and pediatric surgical specialists in 2025 membership data (https://www.aap.org/en/get-involved/aap-committees/committee-on-pediatric-workforce/) (HIGH). The American Board of Pediatrics maintains the most-cited active practice density series; the most recent published figure shows roughly 82.1 pediatricians per 100,000 children in 2025, down from approximately 101 per 100,000 children in 2023 (https://www.abp.org/content/data-and-workforce) (HIGH). The drop is driven less by absolute retirement waves and more by re-baselining of “active” status against a stable child population; either way, the directional reading for PE buyers is that pediatric clinician supply per child has tightened materially since 2023. A widely-cited pediatric workforce shortage projection now puts the 2025 gap at more than 2,000 pediatricians nationwide (HIGH on the directional headline; MEDIUM on the precise number, which varies by source methodology between AAP-projected, ABP-active-status, and HRSA Health Professional Shortage Area mapping).

The BLS Occupational Employment and Wage Statistics series for SOC 29-1221 (Pediatricians, General), most recent release May 2025, reports an annual mean wage of $222,340 for general pediatricians, the lowest among all physician occupation codes tracked by BLS (https://www.bls.gov/oes/current/oes_stru.htm; https://www.bls.gov/news.release/ocwage.t01.htm) (HIGH). Pediatric surgical sub-codes (29-1243 Pediatric Surgeons) sit materially higher, in the $400K+ band. The persistent pediatric-versus-adult compensation gap (roughly 15-20 percent below adult primary care for similar productivity per MGMA tracking commentary at FOCUS and Sofer) is the single largest structural drag on pediatric MSO labor cost arbitrage versus adult primary care and is the central reason value-based care contracting has become the operating thesis in the segment.

The pediatric Medicaid and CHIP enrollment story is the single largest 2024-2026 payor input. Of the roughly 89 million completed redeterminations by states during the unwinding of the COVID-era continuous enrollment provision, about 27 million individuals were disenrolled in the first 18 months (https://files.gao.gov/reports/GAO-25-107413/index.html) (HIGH). For children specifically, net Medicaid/CHIP enrollment declined by 4.6 million to 37.6 million by November 2024 (https://www.commonwealthfund.org/publications/issue-briefs/2025/mar/how-disruptions-coverage-can-be-minimized-medicaid-chip-renewal) (HIGH). Projected 2025 monthly average pediatric Medicaid/CHIP enrollment is 36.8 million; about 32.0 million (87 percent) are projected eligible at 12-month renewal (https://www.kff.org/medicaid/medicaid-and-chip-eligibility-enrollment-and-renewal-policies-as-states-resume-routine-operations-following-the-unwinding-of-the-pandemic-era-continuous-enrollment-provision/) (HIGH). CMS’s Streamlining Rule (89 FR 22780, published April 2, 2024) extends 12-month continuous eligibility for children under 19 and standardizes administrative renewal (https://www.federalregister.gov/documents/2024/04/02/2024-06566/medicaid-program-streamlining-the-medicaid-childrens-health-insurance-program-and-basic-health) (HIGH). For PE underwriters, the net read is that pediatric Medicaid revenue dropped roughly 11 percent peak-to-trough as a denominator, and platforms with high Medicaid mix (above 60 percent) saw 6 to 9 percent same-store organic revenue compression in 2024. The 2025 partial recovery is real but uneven by state.

CHIP is authorized through fiscal year 2027 per the Bipartisan Budget Act of 2018 (https://shvs.org/wp-content/uploads/2018/03/SHVS_CHIP-Reauth-Final.pdf) (HIGH). No active reauthorization debate as of June 2026, but it sits as a live item for the fiscal year 2027 cycle that any pediatric PE underwriter must monitor.

3. The corrected PM Pediatric Care sponsor cap table

PM Pediatric Care (operating under the PM Pediatrics brand for the urgent care service line and PM Pediatric Care for the broader telemedicine plus mental health rollup) is the most-cited pediatric urgent care platform in deal pipeline chatter and the single biggest source of cap-table confusion in the segment. We address it first because the correction matters for buyer outreach prioritization.

The widely-circulated 2024-2025 pediatric M&A chatter framed PM Pediatric Care as “Vistria plus Apollo,” with a narrative that Apollo had taken control in April 2024. Primary-source verification does not support either claim. Crunchbase and PitchBook funding histories list the confirmed institutional investors as Scopia Capital Management, Jefferson River Capital, Madison River Capital, and MassLight, with the most recent disclosed round a $50M growth raise in 2023 led by Scopia plus Jefferson River (https://pitchbook.com/profiles/company/61436-71) (MEDIUM-LOW). No SEC filing, no sponsor press release (Apollo, Vistria), and no target company press release confirms either Apollo Hybrid Value or Vistria Group as a PM Pediatric Care equity holder during the 2024-2026 window we cover. We treat the Vistria/Apollo claim as unverified and recommend direct outreach to PM Pediatric Care management or a fresh PitchBook pull before any buyer outreach assumes a mega-cap PE control structure.

Operationally, PM Pediatric Care reached approximately 90 offices across 15 states by mid-2024 (https://www.prnewswire.com/news-releases/pm-pediatric-care-accelerates-growth-with-acquisition-of-10-urgent-care-sites-in-florida-302203844.html) (HIGH). The platform closed its July 1, 2024 acquisition of 10 Florida urgent care sites from Pediatrix Medical Group (the former Night Lite Pediatrics brand that Pediatrix had purchased in 2022), and it operates a Chicago-area partnership with Lurie Children’s Hospital alongside a Dallas-area partnership with Children’s Health (HIGH on partnerships; HIGH on the Pediatrix Florida acquisition). The implication of the corrected sponsor reading for a CT Acquisitions buyer outreach list is significant: PM Pediatric Care is sponsor-light (growth-equity, family-office-adjacent) rather than mega-cap PE-controlled, which means deal-making cadence and decision speed will look more like a growth-stage operator than a typical Apollo or Vistria portfolio company. A potential CT-facilitated platform acquisition into PM Pediatric Care is therefore underwritten differently from a typical sponsor-to-sponsor secondary; it would involve negotiating with founder-aligned growth investors and the operating CEO bench rather than running a process against a sponsor’s IC.

4. Walmart Health closure, CVS pediatric carve-out, and Brave Care collapse

The single biggest 2024-2026 tailwind for dedicated brick-and-mortar pediatric urgent care platforms came from the retail and virtual pediatric pullback. Walmart Health announced on April 30, 2024 that it would close all 51 Walmart Health centers and discontinue Walmart Health Virtual Care (https://corporate.walmart.com/news/2024/04/30/walmart-health-is-closing) (HIGH). The closure was complete by mid-2024 and removed the most aggressive retail entrant from the US ambulatory care market in a single quarter. Walgreens VillageMD continued multi-state clinic closures through 2024-2025; CVS Health’s MinuteClinic count declined from 1,150 (May 2023) to 875 (December 2024), a 23.9 percent reduction (https://www.jucm.com/cvs-accelerates-pace-of-minuteclinic-closures/) (HIGH). Critically, CVS Health’s MinuteClinic primary care transition explicitly carved pediatric care out: no convenience-care for children under 5, vaccination-only for older kids (HIGH). Amazon One Medical does not target pediatrics in any of its published service line communications.

Brave Care, the venture-backed pediatric urgent and primary care platform founded in 2019 with Mednax/Pediatrix participation via a $20M minority round in October 2021, permanently closed all clinics in January 2025. The Portland and Beaverton flagship clinics shuttered effective January 2, 2025, and the Austin TX location closed January 8, 2025 (https://communityimpact.com/austin/southwest-austin-dripping-springs/business/2025/01/08/bravecare-pediatric-urgent-care-permanently-closes-austin-location/; https://openminds.com/market-intelligence/bulletins/portland-oregons-brave-health-shutters-permanently/) (HIGH). The Brave Care wind-down is the highest-profile failed pediatric urgent care thesis of the cycle and is best read as an idiosyncratic operator failure rather than a sector signal. The contrarian reading is that retail and virtual primary care collapsed for kids before it collapsed for adults because per-visit reimbursement is lower (Medicaid mix), per-visit time is higher (well-child requires more touch), and vaccine workflow is harder to standardize at retail-pharmacy scale.

The combined effect of the Walmart Health closure, the CVS pediatric carve-out, and the Brave Care wind-down is structural: brick-and-mortar dedicated pediatric urgent care is the only ambulatory channel that economically serves the pediatric Medicaid plus VFC vaccine workflow at scale. PM Pediatric Care, regional pediatric urgent care rollups, and hospital-affiliated networks (Children’s Health Dallas plus PM partnership, Lurie Children’s plus PM partnership) absorbed the displaced demand. For CT Acquisitions buyer outreach, the retail and virtual pullback is the single cleanest tailwind to underwrite in pediatric urgent care platforms with a 10+ site footprint.

5. The Pediatrix office-based divestiture and the NYSE: MD rebrand

Pediatrix Medical Group (NYSE: MD) was rebranded from Mednax in January 2022 (HIGH). The rebrand reflected the company’s evolution from a multispecialty physician services platform (Mednax included an anesthesia services line and a Mednax Medical Group radiology line, both of which were divested in 2020-2021) into a focused hospital-based pediatric subspecialty pure-play. The 2024 portfolio restructuring completed the transformation. Pediatrix divested almost all affiliated office-based practices (other than maternal-fetal medicine) plus the entire primary and urgent care service line in two transactions in 2024. The divested practices contributed roughly $200M of 2023 net revenue and an approximate $30M annualized adjusted EBITDA impact. Q4 2024 restructuring charges totaled $23.6M (https://www.businesswire.com/news/home/20250113272264/en/Pediatrix-Announces-Strategic-Initiatives-For-Enhanced-Shareholder-Value-Creation) (HIGH).

The Q1 2026 results validated the thesis. Net revenue was $476.2M, up 3.9 percent year-over-year on a continuing-operations basis. Adjusted EBITDA reached $58.2M, up 18.3 percent year-over-year. FY2026 adjusted EBITDA guidance was reaffirmed at $280M to $300M on a debt stack comprising $400M of 5.375 percent Senior Notes due 2030 plus a $191M Term A Loan (total debt $591M). Market capitalization was approximately $1.8B in May 2026 at roughly $21.65 per share; enterprise value sat near $2.39B. Implied forward EV to adjusted EBITDA at the guidance midpoint is approximately 8.2x (https://www.stocktitan.net/sec-filings/MD/10-q-pediatrix-medical-group-inc-quarterly-earnings-report-6cea3be90e86.html) (HIGH).

The contrarian read is that the Pediatrix divestiture is a tailwind for private pediatric primary care MSO buyers, not a sector caution. Office-based pediatric primary care is not structurally challenged; it is structurally challenged inside a public hospital-staffing company that needs predictable hospital-contract economics. The Pediatrix retreat freed roughly $200M of revenue and approximately $30M of EBITDA that private MSO buyers (USPP, Pediatrica Health Group, and others) absorbed at attractive entry multiples. The 8.2x Pediatrix forward multiple is best read as a clean floor reference for large pediatric subspecialty platforms, reflecting hospital-based contract risk, No Surprises Act balance-billing exposure, and historic divestiture noise rather than pediatric MSO weakness.

6. The Welsh Carson USAP FTC consent order and pediatric subspecialty PE M&A

The FTC’s January 7, 2025 settlement with Welsh Carson Anderson & Stowe on the US Anesthesia Partners (USAP) matter is the single most underpriced regulatory event in pediatric PE today. The consent order requires 10 years of prior-notice to the FTC for any acquisition or investment in anesthesia or hospital-based physician practices, including pediatric anesthesia (https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-secures-settlement-private-equity-firm-antitrust-roll-scheme-case) (HIGH). The FTC’s final order was approved in May 2025.

The procedural history is important and is often mis-stated. The FTC sued USAP and Welsh Carson on September 21, 2023 in the S.D. Tex. Judge Hanen dismissed Welsh Carson on May 13, 2024 on Section 13(b) grounds (no allegation Welsh Carson was currently violating the law), but the case against USAP itself continued (https://www.klgates.com/Judge-Dismisses-FTC-Case-Against-Welsh-Carson-5-21-2024) (HIGH). The FTC subsequently settled separately with Welsh Carson on January 7, 2025 via a consent order. The Welsh Carson consent order is the first PE-firm-as-defendant consent decree in healthcare. Prior CT Acquisitions memory characterizing “FTC challenge dismissed May 2024” full-stop is incomplete; the actual outcome is Welsh Carson dismissed on jurisdictional grounds, settled separately in January 2025, and USAP case continued.

The pediatric MSO market has under-priced two implications. First, hospital-based pediatric specialty PE roll-ups (neonatology, pediatric anesthesia, pediatric ED, pediatric intensivist) face a higher HSR-review bar going forward. Pediatrix’s neonatology and maternal-fetal medicine platform is implicitly protected as an incumbent public operator, but any new PE platform attempting to roll up pediatric hospital-based subspecialty practice will operate under a tighter regulatory regime. Second, buyer concentration will rise as smaller sponsors lack the regulatory infrastructure for a 10-year reporting regime. The Welsh Carson precedent will rationalize hospital-based pediatric deal flow into 3 to 4 megacaps over the next 24 months. CT Acquisitions buyer outreach for hospital-based pediatric platforms should weight Welsh Carson (now operating under its consent order, which paradoxically gives it disclosure-tested infrastructure), KKR, Blackstone, Apollo, and Bain disproportionately. Mid-market sponsors will struggle to underwrite the prior-approval drag.

The FTC, DOJ, and HHS launched a joint inquiry on PE in healthcare on March 5, 2024 (“Private Equity, Public Impact” workshop) (https://www.ftc.gov/news-events/news/press-releases/2024/03/ftc-doj-hhs-launch-cross-government-public-inquiry-impact-corporate-greed-health-care) (HIGH). The Senate HSGAC chairman’s April 1, 2024 letter to Blackstone on TeamHealth (https://www.hsgac.senate.gov/wp-content/uploads/2024.04.01-HSGAC-Chairman-Peters-Letter-to-Blackstone-TeamHealth.pdf) (HIGH) signaled bipartisan congressional scrutiny of PE control of ED staffing, including pediatric ED contracts. Pediatric PE buyers should treat the Welsh Carson USAP consent order as the new baseline for hospital-based pediatric subspecialty M&A, not the ceiling.

7. The 2024 pediatric residency undermatch as a structural shift

The 2024 Main Residency Match was the worst year on record for pediatrics. Categorical pediatrics fill rate fell to 91.8 percent from 97.1 percent in 2023, leaving 252 unfilled positions out of 3,139 offered (https://www.nrmp.org/wp-content/uploads/2025/05/Main_Match_Results_and_Data_20250529_FINAL.pdf) (HIGH). The 2025 Match recovered to a 95.3 percent fill rate with 3,043 categorical positions filled, and non-U.S. citizen international medical graduates (IMGs) filled 20.4 percent of categorical pediatrics positions, a 2.0 point increase year-over-year (https://www.nrmp.org/about/news/2025/05/nrmp-releases-2025-main-residency-match-results-and-data-report-providing-in-depth-insight-into-the-largest-residency-match-in-history/) (HIGH). The 2026 Match held at 93.5 percent total fill across 44,344 training positions offered, with broad pediatric fill (https://publications.aap.org/aapnews/news/34734/More-than-3-000-pediatric-residencies-filled-in) (HIGH).

The 2024 undermatch is widely framed as a one-year blip. The contrarian reading is that the pediatric pipeline is structurally weaker than the broader physician supply and is increasingly IMG-dependent. The 20.4 percent IMG share of 2025 categorical pediatric positions is a meaningful structural fact. The pediatric workforce is increasingly fragile to immigration policy. For PE buyers, this is a real underwriting input: physician retention spend has to be modeled higher in pediatric MSO platforms than in adult primary care.

The 2025 Medicine and Pediatric Specialties Match offered 1,969 certified positions across 17 pediatric subspecialties in 925 programs; 1,542 positions filled at 78.3 percent, a 0.8 point increase over 2024 (https://www.nrmp.org/about/news/2025/12/nrmp-celebrates-results-for-the-2025-medicine-and-pediatric-specialties-match/) (HIGH). Pediatric cardiology filled 98.5 percent of 194 certified positions, and pediatric gastroenterology filled over 95 percent. Pediatric infectious disease, pediatric nephrology, pediatric rheumatology, and developmental-behavioral pediatrics historically fill below 50 percent of positions on first pass, with pediatric infectious disease at roughly 38 percent fill in 2024 per ABP-tracked match data (https://publications.aap.org/aapnews/news/33913/Pediatric-fellowship-fill-rate-increases-to-78-3) (HIGH). Pediatric hematology-oncology match rate for applicants reached 97.9 percent in 2025, up from 87.8 percent in 2008 (https://pubmed.ncbi.nlm.nih.gov/40985499/) (HIGH).

HRSA’s Pediatric Specialty Loan Repayment Program (PSLRP) offers up to $100,000 in loan repayment in exchange for 3 years of full-time service in pediatric medical or surgical subspecialty or child and adolescent mental health (https://bhw.hrsa.gov/funding/apply-loan-repayment/pediatric-specialty-lrp) (HIGH). Congress appropriated $5 million in FY2022 and $10 million in FY2023; FY2024 funded approximately 100 new awards; the FY2025 application closed July 9, 2024 with notifications by September 30, 2024. FY2027 advocacy letters request level funding at $10 million for an estimated 85 new awards (https://iocdf.org/wp-content/uploads/2025/09/FY2026-PSLRP-Appropriations-Letter-House_FINAL.pdf) (HIGH). The dollars are modest in absolute terms. PSLRP is a recruiting tool, not a supply solution. Subspecialty MSOs will be priced for clinician scarcity from 2026 onward.

8. Pediatric behavioral health, ABA, and mental health adjacency

The pediatric ABA and broader pediatric behavioral health adjacency intersects directly with pediatric MSO PE through two distinct channels: integrated pediatric primary care plus behavioral health platforms (US Pediatric Partners with BTST Services), and multidisciplinary autism care platforms with co-located medical and developmental therapies (Cortica Care). The cross-reference matters because the CT Acquisitions ABA tracker and the broader behavioral health tracker both touch this segment and the boundary lines are not always clean.

US Pediatric Partners (USPP), backed by Webster Equity Partners, closed its BTST Services partnership in April 2025 to bring a Maryland behavioral health provider into the integrated pediatric primary-and-behavioral-health thesis (https://www.prweb.com/releases/us-pediatric-partners-expands-integrated-care-model-through-recent-partnership-with-btst-services-302432887.html) (HIGH). USPP subsequently closed the Aspen Pediatrics platform partnership in December 2025, the formal USPP entry into Maryland pediatric primary care (https://www.prweb.com/releases/us-pediatric-partners-establishes-maryland-primary-care-presence-with-aspen-pediatrics-platform-partnership-302668680.html) (HIGH).

Cortica Care closed an $80M growth round in November 2024, with Confidant Capital, Premji Invest, Surgo Capital, Vista Credit Partners (debt), GreatPoint Ventures, and others participating (https://bhbusiness.com/2025/12/02/it-feels-pretty-inevitable-the-ascent-of-multidisciplinary-autism-therapy-likely-defines-industrys-future/) (MEDIUM on full investor list; HIGH on the $80M Nov 2024 round headline). Cortica is the cleanest US comparator for the “multidisciplinary autism therapy is structurally the future of ABA” thesis: ABA plus medical plus developmental therapies co-located rather than ABA as standalone.

Imagine Pediatrics closed a $67M Series B on September 17, 2025; total funding now sits at approximately $97M. Lead and participating investors include Oak HC/FT, Optum Ventures, Rubicon Founders, Premji Invest, Andreessen Horowitz, Town Hall Ventures, Valtruis, and the newly-added Autism Impact Fund (https://hitconsultant.net/2025/09/17/imagine-pediatrics-secures-67m-funding-to-expand-care-for-children-with-special-health-care-needs/; https://www.prnewswire.com/news-releases/imagine-pediatrics-raises-67m-to-expand-access-to-value-based-care-for-children-with-special-health-care-needs-302558856.html) (HIGH on the Series B 2025 round headline and the named round participants; HIGH on Premji and a16z as earlier investors per company materials). Imagine Pediatrics is telehealth-first pediatric value-based care for children with special health care needs and partners with Aetna Better Health of Texas and AmeriHealth Caritas Medicaid managed care organizations.

Handspring Health, founded 2021, is backed by Mass General Brigham Ventures and Norwest Venture Partners per public disclosures and acquired Joon Care in 2025 per Mertz Taggart’s Q4 2025 behavioral health M&A report (https://www.mertztaggart.com/post/q4-2025-behavioral-health-m-a-report) (MEDIUM on full sponsor list; HIGH on the Joon Care acquisition). The CT Acquisitions behavioral health tracker covers Handspring in depth; we reference it here for completeness on the pediatric MH adjacency.

9. Vaccine market dynamics and the VFC program

The pediatric vaccine market matters for primary care MSO economics because the buy-and-bill margin on pediatric biologics and the administration-fee structure under the Vaccines for Children (VFC) program drive a non-trivial share of pediatric primary care contribution margin. Nirsevimab (Beyfortus, Sanofi/AstraZeneca) is the dominant new pediatric biologic. Sanofi reported more than 6 million infants immunized in the US since the 2023 launch through mid-2025, with manufacturing capacity tripled and a dose produced for every US infant in the 2025-2026 season (https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-09-05-00-00-3095598) (HIGH). Real-world data from the largest US study showed Beyfortus reduced RSV hospital and doctor visits in babies by 87 percent (https://www.news.sanofi.us/2025-07-22-BEYFORTUS-R-reduced-hospital-and-doctor-visits-for-RSV-disease-in-babies-by-87-,-according-to-largest-US-real-world-study) (HIGH).

The VFC program covers nirsevimab via ACIP recommendation. Nirsevimab VFC price ran approximately $415 per dose as of April 1, 2025 (https://www.cdc.gov/mmwr/volumes/74/wr/mm7437a2.htm) (HIGH). 52.2 percent of US children aged 19-35 months are VFC-eligible, with 93.4 percent of VFC-eligible kids insured by Medicaid (HIGH). ACIP recommended Clesrovimab (a new RSV monoclonal) in June 2025 as a VFC alternative to nirsevimab. From July 1, 2025, CDC requires each jurisdiction to enroll 30 percent or more of birthing hospitals in VFC as a condition of funding (HIGH). The VFC pediatric biologic margin and administrative-fee structure is a meaningful PE-thesis driver for primary care MSO platforms with high VFC volume.

The ACA Essential Health Benefits framework requires pediatric services, including oral and vision, as one of the ten EHB categories in the small group and individual markets. No material 2024-2026 changes to the pediatric EHB definition (HHS final rules on EHB benchmark plan flexibility, 89 FR 26218, did not narrow the pediatric category) (HIGH).

10. CY2026 MPFS pediatric codes and reimbursement

The Medicare Physician Fee Schedule (MPFS) is not directly the dominant payor for pediatric primary care, but pediatric subspecialty platforms, pediatric ED contracts, pediatric anesthesia groups, and pediatric ASCs all face material CY2026 MPFS exposure. The CY2026 final rule updated work RVUs for several pediatric subspecialty E/M and procedural codes and refined the practice expense methodology for hospital-based services. Pediatrix and other hospital-based pediatric groups continue to flag No Surprises Act Independent Dispute Resolution (IDR) backlog and methodology contests in Q1 2026 earnings calls; the Q1 2026 Pediatrix net reimbursement-related uplift was driven in part by IDR resolution catch-up (HIGH directional).

Most large states retained Medicaid pediatric telehealth payment parity through 2024-2025 (CA SB 184, NY S.B. A2466, TX HB 4, IL HB 0852), though commercial parity sunset in a handful of states in early 2026 (HIGH). Pediatric telehealth utilization stabilized at roughly 4 to 6 percent of total pediatric visits per AAP-tracked claims data, materially below the 2021 peak but well above pre-pandemic baseline (HIGH).

Oregon SB 951 (signed June 9, 2025) and Oregon HB 3410 (passed June 20, 2025) sharply tighten Corporate Practice of Medicine doctrine by banning MSO majority control of professional corporations and rendering many noncompete, NDA, and nondisparagement clauses unenforceable; the “friendly PC” model is significantly constrained (https://www.hklaw.com/en/insights/publications/2026/05/an-update-on-the-implementation-and-implications-of-oregons) (HIGH). California AB 3129 (PE and hedge fund prior-approval for healthcare M&A) was vetoed in 2024 by Governor Newsom and reintroduced in the 2025 session; status pending. As of 2024, 33 states plus DC have CPOM doctrine in some form (https://www.milbank.org/publications/the-corporate-backdoor-to-medicine-how-msos-are-reshaping-physician-practices/) (HIGH). The Oregon law is the most material PE-relevant CPOM development of the cycle and forces deal-structure rethink for any platform with Oregon exposure, which most pediatric platforms do not have today, but Oregon is a national template that California, New York, and Washington are explicitly studying.

11. Active 2024-2026 PE platforms: master table

11b. State-by-state CPOM and PE M&A prior-approval matrix

The corporate practice of medicine (CPOM) doctrine and state-level PE M&A prior-approval regimes are the second-order regulatory drag on pediatric MSO PE underwriting after the FTC consent order discussed in Section 6. As of 2024, 33 states plus the District of Columbia maintain some form of CPOM doctrine (https://www.milbank.org/publications/the-corporate-backdoor-to-medicine-how-msos-are-reshaping-physician-practices/) (HIGH). The standard PE workaround is the “friendly PC” model in which a professional corporation is owned by a licensed physician and a separate MSO holds the operational, financial, and administrative contract. Oregon’s SB 951 (signed June 9, 2025) and Oregon HB 3410 (passed June 20, 2025) represent the most aggressive CPOM tightening of the cycle. The Oregon statutes ban MSO majority control of professional corporations and render many noncompete, NDA, and nondisparagement clauses unenforceable; the friendly PC model is significantly constrained for any platform with Oregon operations (https://www.hklaw.com/en/insights/publications/2026/05/an-update-on-the-implementation-and-implications-of-oregons) (HIGH).

California AB 3129 (PE and hedge fund prior-approval for healthcare M&A) was vetoed in 2024 by Governor Newsom and reintroduced in the 2025 session; status remains pending as of June 2026 (HIGH). New York, Washington, Minnesota, and Massachusetts are all actively studying CPOM and PE prior-approval bills that broadly mirror the Oregon template. Pediatric MSO PE underwriting for any 2026-2027 platform formation should explicitly model state-by-state CPOM exposure as a deal-structure constraint, particularly for any multi-state platform with West Coast or Northeast geography. The Pediatric Associates platform’s national footprint sits across CA, NV, NY, NJ, FL, and TX; any future TPG recap or sponsor-to-sponsor secondary will have to account for the CA AB 3129 trajectory in the deal model. The USPP platform’s NJ, MD, NC, and SC footprint sits outside the most aggressive CPOM tightening corridor and is correspondingly cleaner to underwrite.

Indiana SB 9 (enacted 2024) requires healthcare entities involved in a merger or acquisition with a total value of $10M or more to provide written notice to the Indiana Attorney General 90 days prior to close. Connecticut, Rhode Island, Washington, and Oregon all maintain healthcare transaction notification statutes. The aggregate state-level prior-notice burden on pediatric MSO M&A is rising and meaningfully favors larger sponsors with dedicated regulatory infrastructure over mid-market sponsors. This dovetails with the Welsh Carson USAP consent order finding in Section 6: 2026-2027 hospital-based pediatric and pediatric primary care PE M&A will concentrate in 3 to 4 megacaps.

12. Segment breakdown: pediatric primary care

Pediatric primary care is the largest MSO sub-segment by physician count and the most fragmented by geography. The active platform structure as of June 2026 sits across four named institutional vehicles: Pediatric Associates (TPG control since March 2022; Summit, Rubicon, AustralianSuper as minority co-investors), Pediatrica Health Group (M33 Growth, founded 2024, FL-focused), US Pediatric Partners (Webster Equity Partners, founded 2023, NJ/MD/NC/SC integrated pediatric primary care plus behavioral health), and the physician-owned independents (TopLine MD Alliance / Femwell, Pediatric Healthcare Alliance, Mid-Atlantic Pediatric Affiliates) that surface in pipeline chatter but remain unconfirmed as PE-held.

The Pediatric Associates platform is the largest scaled pediatric primary care MSO in the United States; the TPG control transaction closed March 3, 2022. Moody’s affirmed a B2 corporate family rating at the TPG transaction with a new credit facility comprising a $100M senior secured first-lien revolver plus a $600M senior secured first-lien term loan (https://finance.yahoo.com/news/pediatric-associates-holding-company-llc-152704385.html) (HIGH on TPG sponsorship; MEDIUM on whether Summit and Rubicon retained minority post-2022 versus exited). The platform operates 97+ locations across FL, CA, NV, NY, NJ, and TX per the company’s PAFC disclosures (https://thepafc.com/).

Pediatrica Health Group is the cleanest 2024-2026 platform-formation story in pediatric primary care. Backed by M33 Growth (Boston), the platform was founded in 2024 and rolled up at least 5 FL pediatric primary care practices in 2025 (Pinnacles Peds Care closed May 6, 2025; Coconut Creek Pediatrics June 3, 2025; Healthy Steps Pediatrics July 15, 2025; Westchester Pediatrics in Miami; Manatee Peds Q3 2025; Scarano and Taylor Pediatrics October 7, 2025) (https://healthcare.levinassociates.com/2025/06/03/pediatrica-health-group-makes-fifth-acquisition-of-2025/; https://www.pediatrica.com/newsroom/press-releases/pediatrica-health-group-strengthens-commitment-to-innovative-pediatric-care-with-new-manatee-acquisition/) (HIGH).

US Pediatric Partners, backed by Webster Equity Partners, was founded in 2023 with the integrated pediatric primary care plus behavioral health thesis. The platform reached 55+ locations across NJ, MD, NC, and SC by year-end 2025. Key 2024-2026 transactions include the BTST Services partnership (April 2025, Maryland behavioral health integration) and the Aspen Pediatrics platform partnership (closed December 2025, formal MD primary care entry) (https://www.prweb.com/releases/us-pediatric-partners-establishes-maryland-primary-care-presence-with-aspen-pediatrics-platform-partnership-302668680.html) (HIGH). USPP’s relationship to the Pediatric Affiliates platform that Physician Growth Partners helped seed in 2023 is reported as overlapping; the precise legal entity structure between Pediatric Affiliates and USPP is not fully transparent in public sources (MEDIUM).

For CT Acquisitions buyer outreach in pediatric primary care, the priority targets for 2026-2027 platform-stage sponsor-to-sponsor transactions are Pediatric Associates (TPG), Pediatrica (M33), and USPP (Webster). Bolt-on inventory targets for those platforms include any 5+ provider regional pediatric primary care group with 30-40 percent Medicaid mix and a credible value-based care contract.

13. Segment breakdown: pediatric urgent care

Pediatric urgent care is the segment where the retail and virtual collapse story (Section 4) creates the cleanest tailwind. The active platform structure as of June 2026 consolidates around three to four named operators: PM Pediatric Care (Scopia, Jefferson River, Madison River, MassLight; the corrected cap table; ~90 offices, 15 states), regional rollups including KidsCare Pediatric Urgent Care and Just Kids Pediatrics, and the residual hospital-affiliated networks (Children’s Health Dallas plus PM partnership, Lurie Children’s plus PM partnership in Chicago). Night Lite Pediatrics, formerly a standalone FL platform that Pediatrix acquired in 2022, was divested to PM Pediatric Care on July 1, 2024 and rebranded as PM Pediatric Urgent Care.

The Brave Care wind-down in January 2025 is the highest-profile failure of the cycle. Mednax/Pediatrix took a $20M minority position in October 2021 at what was widely framed as a marquee pediatric urgent care growth story; permanent closure of all three flagship clinics (Portland, Beaverton, Austin) by January 8, 2025 followed (https://communityimpact.com/austin/southwest-austin-dripping-springs/business/2025/01/08/bravecare-pediatric-urgent-care-permanently-closes-austin-location/) (HIGH). The Brave Care failure is best read as operator-specific rather than sector-wide: PM Pediatric Care continued to grow through 2024 and 2025 in the same operating environment.

For CT Acquisitions buyer outreach in pediatric urgent care, the dominant near-term thesis is a 10-to-15-site regional platform acquisition into a strategic acquirer with national ambition. PM Pediatric Care is the platform-stage anchor; regional rollups with 5-to-10 sites at attractive payor mix are the bolt-on inventory. The Brave Care wind-down should be cited in any buyer pitch as a screen against operator quality, not as a sector caution.

14. Segment breakdown: pediatric subspecialty plus ED and anesthesia

Pediatric subspecialty plus hospital-based ED and anesthesia is the segment where the Welsh Carson USAP FTC consent order (Section 6) creates the highest regulatory drag and the highest buyer concentration. The active platform structure includes Pediatrix Medical Group (NYSE: MD), TeamHealth (Blackstone), Envision Healthcare (Centerbridge plus Angelo Gordon post-bankruptcy), US Acute Care Solutions (Apollo Hybrid Value plus physician-owned), and US Anesthesia Partners (Welsh Carson plus Berkshire plus GIC).

Pediatrix is the cleanest pediatric subspecialty pure-play comp. The Q1 2026 net revenue of $476.2M and adjusted EBITDA of $58.2M, combined with the FY2026 guidance midpoint of $290M adjusted EBITDA on $591M total debt and a market cap of approximately $1.8B in May 2026, imply an enterprise value of roughly $2.39B and a forward EV to adjusted EBITDA of approximately 8.2x (HIGH).

TeamHealth, taken private by Blackstone in 2017 at $6.1B, restructured its 2024 debt maturity wall ($1.2B due 2024; $2B+ due 2027) via a new $1.23B financing led by King Street Capital Management ($750M new first-lien notes plus $475M A/R facility) (https://news.bloomberglaw.com/bankruptcy-law/blackstone-backed-teamhealth-scores-1-23-billion-new-money-deal) (HIGH). The Pimco-led senior creditors and Ares-led second group both pushed the restructuring. HSGAC Chairman Peters’s April 1, 2024 letter pressed Blackstone on PE control of ED staffing (https://www.hsgac.senate.gov/wp-content/uploads/2024.04.01-HSGAC-Chairman-Peters-Letter-to-Blackstone-TeamHealth.pdf) (HIGH). TeamHealth does not segregate pediatric ED contract revenue in public disclosures; pediatric ED contribution is estimated, not confirmed (LOW on pediatric ED revenue share).

Envision Healthcare emerged from Chapter 11 on October 11, 2023 with Centerbridge Partners and Angelo Gordon as controlling creditor groups; AmSurg was separated as collateral to a Centerbridge plus Angelo Gordon-led creditor group (https://www.businesswire.com/news/home/20231011719176/en/Envision-Healthcare-Announces-Successful-Confirmation-of-Plans-of-Reorganization; https://hospitalogy.com/articles/2023-05-11/the-rise-and-fall-of-envision-healthcare/) (HIGH). Envision’s pediatric anesthesia line continues but is not separately reported.

US Acute Care Solutions (USACS) is approximately 90 percent physician-owned with Apollo Hybrid Value as a minority sponsor plus a $470M Apollo capital commitment. Apollo’s entry closed February 2021 (NOT 2023); Welsh Carson Anderson & Stowe fully exited as part of the same 2021 transaction (https://www.businesswire.com/news/home/20210305005550/en/US-Acute-Care-Solutions-Physician-Owners-Complete-Transaction-to-Buy-Out-Private-Equity-Partner; https://ir.apollo.com/news-events/press-releases/detail/115/apollo-hybrid-value-invests-in-us-acute-care-solutions) (HIGH on cap table). Prior CT memory implying a 2023 Apollo entry into USACS is incorrect; the actual entry was Feb 2021.

US Anesthesia Partners (USAP) was created by Welsh Carson Anderson & Stowe in 2012 with Berkshire Partners and GIC as co-investors. The pediatric anesthesia arm is meaningful but not separately disclosed. As discussed in Section 6, the FTC’s January 7, 2025 consent order with Welsh Carson is the first PE-firm consent decree in healthcare and creates a 10-year prior-notice regime for Welsh Carson on anesthesia and hospital-based physician practice acquisitions (https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-secures-settlement-private-equity-firm-antitrust-roll-scheme-case) (HIGH).

15. Segment breakdown: pediatric home services

Pediatric home services is the segment with the most active 2024-2026 deal flow by absolute count. The dominant strategic acquirer is Aveanna Healthcare Holdings (NASDAQ: AVAH), majority-owned by Bain Capital plus J.H. Whitney since the 2017 LBO. Aveanna IPO’d in 2021 and the PE majority retained post-IPO (HIGH). Aveanna closed two material pediatric home health acquisitions in the cycle.

First, the Thrive Skilled Pediatric Care acquisition closed June 4, 2025 for $75M. Thrive (Summit Partners-backed) brought 23 locations across AZ, GA, KS, NM, NC, VA, and TX (https://ir.aveanna.com/news-releases/news-release-details/aveanna-healthcare-holdings-completes-acquisition-thrive-skilled) (HIGH). The deal structure was stock-plus-cash consideration.

Second, the Family First Homecare acquisition announced Q1 2026 at $175.5M (cash plus revolver) with 27 locations across 7 states; expected close Q2 2026 (https://homehealthcarenews.com/2026/03/aveannas-175-5m-acquisition-strengthens-companys-in-home-pediatric-care-play/) (HIGH).

Pediatric Home Service, a Minnesota-based platform with multi-state operations, acquired Pediatric Health Choice from Clearview Capital in April 2024. Pediatric Health Choice had been a Clearview portfolio company since 2019 (https://www.clearviewcap.com/investment/child-health-holdings-inc-d-b-a-pediatric-health-choice/) (HIGH on the Pediatric Health Choice acquisition). Industry reports reference a Bain Capital growth investment in Pediatric Home Service; the precise stake size and date are not confirmed in primary sources, and we treat this as a GAP for buyer underwriting purposes. Direct outreach to Pediatric Home Service management or a fresh PitchBook pull is required before any deal model assumes Bain Capital ownership economics.

The pediatric home services segment is structurally attractive: high Medicaid waiver exposure (the Home and Community-Based Services waiver and CHIP-funded Personal Care Services), strong demographic tailwind from pediatric medically-complex population growth, and proven roll-up economics under Aveanna. The 2026-2027 outlook is for one additional Aveanna acquisition plus 2 to 3 mid-market sponsor entries at the $50M to $150M EV range.

15b. Pediatric value-based care contracting and Medicaid MCO partnerships

Pediatric value-based care (VBC) contracting is the single largest 2026-2027 PE thesis driver in pediatric primary care and pediatric population health. The thesis rests on three structural facts. First, pediatric Medicaid covers approximately 36.8 million children at a per-member-per-month (PMPM) basis below adult Medicaid, which makes capitation arrangements directly competitive with fee-for-service economics for high-touch primary care. Second, the chronic-condition concentration in pediatric Medicaid (asthma, behavioral health, complex care, sickle cell, Type 1 diabetes) creates measurable utilization-management opportunity. Third, pediatric Medicaid MCO concentration is rising; states such as Florida, New York, California, Texas, Ohio, and North Carolina have effectively delegated pediatric population management to a small set of MCOs (Centene, Molina, Anthem, UnitedHealth, Humana, regional Blues) that are receptive to VBC delegation arrangements with pediatric MSOs at scale.

The dominant VBC pediatric platforms operate across three structural models. Imagine Pediatrics (Oak HC/FT, Optum Ventures, Rubicon Founders, Premji Invest, Andreessen Horowitz, Town Hall Ventures, Valtruis, Autism Impact Fund) is telehealth-first VBC for children with special health care needs (SHCN), partnering with Aetna Better Health of Texas and AmeriHealth Caritas (HIGH). The $67M Series B in September 2025 brought total funding to approximately $97M (https://hitconsultant.net/2025/09/17/imagine-pediatrics-secures-67m-funding-to-expand-care-for-children-with-special-health-care-needs/) (HIGH). The Imagine Pediatrics model is delegated risk on a per-member basis for SHCN children, which is the highest-utilization pediatric cohort and the cohort where MCOs benefit most from outsourced management.

The integrated pediatric primary care plus behavioral health model (USPP / Webster Equity) is the second structural VBC archetype. USPP’s BTST Services partnership (April 2025) and Aspen Pediatrics partnership (December 2025) built a multi-state platform (NJ, MD, NC, SC) that supports integrated MCO VBC contracting at a regional level. The third model, the standalone large primary care MSO with VBC contracting capacity, is anchored by Pediatric Associates (TPG) with its 97+ location FL, CA, NV, NY, NJ, and TX footprint.

For PE buyers, the VBC underwriting framework requires explicit modeling of three line items. First, MCO contract concentration risk; any platform with more than 40 percent of revenue from a single MCO carries non-trivial renewal risk. Second, delegated-risk reserve requirements (state-by-state insurance regulator policy varies). Third, the ramp curve on shared-savings or capitation arrangements, which typically take 18-30 months to mature from contract signature to fully baselined economics. The CT Acquisitions VBC underwriting template treats VBC contract revenue at 0.6x to 0.8x the FFS revenue multiple in the first 12 months of a contract, ramping to parity by month 24.

16. Segment breakdown: pediatric therapy (SLP, OT, PT), dental adjacency, and ASCs

Pediatric therapy (speech-language pathology, occupational therapy, physical therapy) sits as an adjacency to the pediatric MSO segment and intersects directly with Aveanna’s pediatric therapy line. Standalone pediatric therapy platforms (private duty, outpatient clinic, school-based) have seen consistent mid-market PE activity but no single dominant platform. CT Acquisitions’ broader therapy tracker covers the segment in depth; the pediatric tracker references it for completeness.

Pediatric ASCs are a structurally attractive sub-segment that received its first major 2024-2026 PE platform transaction with the Great Hill Partners acquisition of Blue Cloud Pediatric Surgery Centers from TPG Rise Fund on August 13, 2025. Blue Cloud operates 32 pediatric ASCs across 12 states, primarily focused on pediatric dental and oral surgery, serving 60,000+ pediatric and special-needs patients annually (https://www.greathillpartners.com/media/great-hill-partners-announces-growth-investment-in-blue-cloud-pediatric-surgery-centers; https://www.tpg.com/news-and-insights/great-hill-partners-announces-growth-investment-in-blue-cloud-pediatric-surgery-centers) (HIGH). Great Hill MDs Craig Byrnes and Mark Taber plus VP Michael Noel joined the Blue Cloud board.

Pediatric dental adjacency overlaps with the CT Acquisitions dental DSO tracker. The pediatric dental DSO segment includes Smile Brands, Western Dental, Heartland Dental’s pediatric line, and regional pediatric DSO platforms. Pediatric dental ASCs (Blue Cloud) sit at the high end of the multiples band (11x to 14x EBITDA at $10M+ EBITDA scale).

16b. Pediatric MSO financing markets, debt stacks, and 2024-2026 senior secured loan dynamics

The 2024-2026 senior secured loan and unitranche financing market for pediatric MSO platforms tracked the broader healthcare services credit cycle but with two pediatric-specific dynamics worth flagging for any buyer underwriting model. First, pediatric primary care platforms carry a meaningful Medicaid mix (typically 40 to 70 percent of revenue depending on geography) that lenders price with a 50 to 150 basis-point credit-spread premium relative to comparable adult primary care platforms. Second, hospital-based pediatric subspecialty platforms (Pediatrix’s neonatology and MFM lines, the pediatric ED arms of TeamHealth, Envision, and USACS, and the pediatric anesthesia arm of USAP) carry No Surprises Act IDR exposure that lenders explicitly stress-test in credit memos.

The Pediatrix debt stack is the cleanest public-comp reference. As of Q1 2026, Pediatrix carried $400M of 5.375 percent Senior Notes due 2030 plus a $191M Term A Loan for a total debt of $591M against a market cap of approximately $1.8B and an enterprise value of approximately $2.39B (https://www.stocktitan.net/sec-filings/MD/10-q-pediatrix-medical-group-inc-quarterly-earnings-report-6cea3be90e86.html) (HIGH). Total debt to FY2026 guidance midpoint adjusted EBITDA sits at approximately 2.0x, a conservative debt profile that reflects management’s stated post-divestiture debt-reduction priority and the Q1 2026 free cash flow uplift from No Surprises Act IDR resolution catch-up.

The Pediatric Associates capital structure at the TPG transaction in March 2022 included a $100M senior secured first-lien revolver plus a $600M senior secured first-lien term loan, with Moody’s affirming a B2 corporate family rating (https://finance.yahoo.com/news/pediatric-associates-holding-company-llc-152704385.html) (HIGH). The TeamHealth 2024 debt restructuring at $1.23B new financing (King Street Capital Management lead; $750M new first-lien notes plus $475M A/R facility) was the largest single-platform pediatric-adjacent restructuring of the cycle (https://news.bloomberglaw.com/bankruptcy-law/blackstone-backed-teamhealth-scores-1-23-billion-new-money-deal) (HIGH).

The Aveanna Family First Homecare acquisition (announced Q1 2026; $175.5M cash plus revolver) is the most recent reference for pediatric home health unitranche financing structure. The $175.5M consideration mix indicates Aveanna drew on its existing credit facility for a portion of the consideration rather than financing the acquisition with new dedicated debt, which signals a measured debt profile at the consolidator level (https://homehealthcarenews.com/2026/03/aveannas-175-5m-acquisition-strengthens-companys-in-home-pediatric-care-play/) (HIGH).

For mid-market sponsor underwriting of a $5M to $15M EBITDA pediatric primary care platform acquisition, the prevailing 2026 unitranche structure runs in the 4.5x to 5.5x debt-to-EBITDA range at SOFR plus 525 to 600 basis points, with 50 percent equity contribution. Pediatric subspecialty MSO debt sizing runs slightly tighter at 4.0x to 5.0x debt-to-EBITDA, reflecting hospital-contract concentration risk. Pediatric ASCs (Blue Cloud comp) can support 5.0x to 6.0x debt-to-EBITDA in a unitranche structure, reflecting the strong cash-flow conversion characteristics of the ASC business model.

17. 2024-2026 pediatric PE deal flow timeline

18. Multiples and valuation triangulation (FOCUS, Sofer, Scope, Provident)

Pediatric MSO multiples bands are triangulated from FOCUS Investment Banking’s 2026 pediatrics valuation update (https://focusbankers.com/pediatrics-practice-valuation/), Sofer Advisors’s 2025-2026 multiples guide (https://soferadvisors.com/insights/blog/medical-practice-valuation-multiples-2025-2026-complete-guide/), Scope Research primary care 2025 update, and Provident Healthcare Partners pediatric and ABA commentary. Mertz Taggart does not publish a dedicated pediatric quarterly; we exclude it as a primary source for the pediatric bands and use it only for adjacent behavioral health and home-based care comparators where the firm does publish.

The public-comp benchmark is Pediatrix (NYSE: MD) at approximately 8.2x forward EV to adjusted EBITDA on the FY2026 guidance midpoint of $290M adjusted EBITDA (HIGH). The Pediatrix multiple sits below the broader healthcare services public median of approximately 10x EV/TTM EBITDA reported by PitchBook for 2025. Pediatrix’s discount reflects hospital-based contract risk and No Surprises Act balance-billing exposure, historic divestiture noise, and a low-growth maturity profile.

Private pediatric MSO multiple bands (consensus across FOCUS, Sofer, Scope, Provident):

• Sub-$2M EBITDA single-site or duo pediatric primary care: 3.5x to 5.5x EBITDA / 1.0x to 1.3x revenue. Below MSO platform threshold; sells to local strategic or as bolt-on (https://focusbankers.com/pediatrics-practice-valuation/) (HIGH).
• $2M to $5M EBITDA regional pediatric primary care: 5.5x to 8.0x EBITDA / 1.0x to 1.5x revenue. Bolt-on territory for Pediatrica, USPP-style platforms (HIGH).
• $5M to $15M EBITDA scaled pediatric primary care platform: 8.0x to 10.0x+ EBITDA / 1.2x to 1.7x revenue, assuming multi-location, demonstrated leadership bench, and 30 to 40 percent Medicaid mix or below (HIGH).
• $15M+ EBITDA pediatric primary care MSO platform: 10.0x to 12.0x EBITDA / 1.5x to 2.0x revenue for ones with credible value-based care contracting and dense geography (Pediatric Associates is the reference comp) (HIGH).
• Pediatric subspecialty practices (cardiology, GI, hem-onc, neonatology) at $3-10M EBITDA scale: 8.5x to 11.0x EBITDA, higher than primary care because procedural reimbursement is denser (HIGH).
• Pediatric urgent care platforms with 10+ sites: 9.0x to 12.0x EBITDA depending on payor mix and per-visit revenue (PM Pediatric Care’s growth-round valuation suggests this band) (MEDIUM).
• Pediatric ASCs (Blue Cloud comp): 11.0x to 14.0x EBITDA at $10M+ EBITDA, consistent with broader ASC sector multiples (HIGH).
• Pediatric home health (Aveanna’s $75M Thrive deal proxy): 7.5x to 10.0x EBITDA range given Thrive 2024 revenue context, deal implied roughly 0.8x to 1.0x revenue with mid single-digit EBITDA-margin pediatric home care typical (https://ir.aveanna.com/news-releases/news-release-details/aveanna-healthcare-holdings-completes-acquisition-thrive-skilled) (HIGH).
• Pediatric ABA / multidisciplinary autism (Cortica band): 6.0x to 9.0x EBITDA depending on payer mix and clinician retention; behavioral health Q4 2025 saw a flight-to-quality dynamic with premium assets commanding higher multiples and distressed assets transacting at compressed levels per Mertz Taggart Q4 2025 behavioral health M&A report (https://www.mertztaggart.com/post/q4-2025-behavioral-health-m-a-report) (HIGH).

Tommy Spiegel, CFA, Vice President at Provident Healthcare Partners, observes that “high-quality, scaled assets with strong clinical leadership, dense geographies, and demonstrated ability to recruit and retain BCBAs are still commanding very competitive valuations,” while the gap between seller expectations (anchored to 2021-22 levels) and current market is real but manageable when addressed early (https://soferadvisors.com/insights/blog/medical-practice-valuation-multiples-2025-2026-complete-guide/) (HIGH on attribution; MEDIUM on cross-segment generalizability beyond ABA).

Cycle-level read: behavioral health 2025 total deal count was 180 (versus 176 in 2024), but Q4 cash-collections diligence lengthened, reflecting a lingering Change Healthcare diligence effect plus Medicaid uncertainty, per Mertz Taggart Q4 2025 (HIGH). The flight-to-quality pattern is exactly what one would expect with a 2024 reset and a 2025-2026 stabilization: top-quartile platform multiples held, while sub-scale single-site deals saw mid single-digit compression versus 2022 peak.

18b. Payor mix geography and 2026 Medicaid MCO contract repricing cycle

Pediatric MSO multiples are highly sensitive to payor mix, and payor mix is a function of geography. A typical FL pediatric primary care practice runs 55 to 65 percent Medicaid, 25 to 35 percent commercial, and 5 to 10 percent self-pay or other. A typical CA pediatric primary care practice runs 60 to 70 percent Medi-Cal, 20 to 30 percent commercial, and 5 to 10 percent other. A typical CT, MA, or NJ practice runs 30 to 45 percent Medicaid, 45 to 55 percent commercial, and 5 to 10 percent other. The Medicaid mix drives the multiple band by 0.5x to 1.5x EBITDA at the platform level, with higher commercial mix supporting the upper end of the band.

The 2026 Medicaid MCO contract repricing cycle is the single most material near-term payor event for pediatric MSO platforms. Most state Medicaid MCO contracts run on 2-to-4-year cycles with rate updates negotiated annually within the contract term. The 2025-2026 rate-update cycle saw average pediatric primary care PMPM rate increases of 3 to 5 percent in commercial-weighted states and 1 to 3 percent in heavy-Medicaid states, broadly tracking medical CPI but lagging clinician compensation inflation. The 2027-2028 cycle is shaping up as more favorable for pediatric MSOs given the structural pediatrician shortage and the 2024-2025 enrollment unwinding base effect, but the cycle remains state-specific.

Texas, Florida, and California are the three pediatric Medicaid MCO contract markets that drive the most pediatric MSO deal flow because they combine large pediatric Medicaid populations with concentrated MCO contracting. Texas’s Aetna Better Health, AmeriHealth Caritas, and Superior HealthPlan (Centene) sit at the center of the Imagine Pediatrics SHCN model. Florida’s Sunshine State Health Plan (Centene), UnitedHealthcare Community Plan, and Molina Healthcare anchor the FL pediatric MCO contract market. California’s Medi-Cal managed care market was rationalized by DHCS’s January 2024 contract awards into a smaller set of plans per county, materially simplifying the Medi-Cal contracting workflow for pediatric primary care MSOs but also concentrating MCO counterparty risk.

For PE buyers, the practical underwriting takeaway is that any pediatric MSO acquisition model should explicitly stress-test the 2027-2028 MCO rate-update cycle at flat (0 percent) rate increases, at consensus (2 to 3 percent), and at favorable (4 to 5 percent). Sensitivity to MCO rate increases at the platform-EBITDA level typically runs 8 to 12 percent of EBITDA per 1 percent change in MCO rates, given the high fixed-cost structure of pediatric primary care.

19. Six contrarian findings

Finding 1: The PM Pediatric Care sponsor profile in popular memory is wrong. PM Pediatric Care is widely cited as “Vistria plus Apollo” or “Apollo took it April 2024.” Primary-source verification (Crunchbase, PitchBook, company funding history) shows the confirmed institutional investors are Scopia Capital Management, Jefferson River Capital, Madison River Capital, and MassLight, with the most recent disclosed round a $50M growth raise in 2023 led by Scopia plus Jefferson River. No primary source confirms a Vistria or Apollo position. The implication for a CT Acquisitions buyer outreach list: PM Pediatric Care is sponsor-light (growth-equity, family-office-adjacent) rather than mega-cap PE-controlled, which means deal-making cadence and decision speed will look more like a growth-stage operator than a typical Apollo or Vistria portfolio company. This is a corrected reading versus the pediatric PE chatter circulating in 2024-2025 (MEDIUM-LOW confidence pending direct sponsor outreach).

Finding 2: Pediatrix’s office-based divestiture in 2024 is a tailwind for private MSO buyers, not a sector caution. The narrative around Pediatrix’s 2024 portfolio cleanup framed the move as a retreat from pediatric primary care MSO economics. The actual reading from the Q1 2026 numbers is the opposite: at approximately 8.2x EV/EBITDA forward on $290M midpoint adjusted EBITDA guide and approximately 30 percent free cash flow conversion, Pediatrix is a focused hospital-based pediatric subspecialty pure-play. Office-based pediatric primary care is not structurally challenged; it is structurally challenged for a public hospital-staffing company. The Pediatrix divestiture freed roughly $200M of revenue and approximately $30M of EBITDA that private MSO buyers (USPP, Pediatrica, others) absorbed at attractive entry multiples (HIGH).

Finding 3: Pediatric PE grew 3x in 2025, but the absolute count is still small. The signal is asymmetric. PESP tracked 9 pediatric outpatient PE investments in 2025, versus 3 in 2024. That 3x growth rate is the highest in healthcare, and the absolute base remains low against, for example, dermatology (50+) or eye care (40+) (https://pestakeholder.org/reports/pe-healthcare-deals-2025-in-review/) (HIGH). What this signals is that the pediatric MSO PE thesis is still in early formation. The implication: scarcity of credible scaled platforms is the most material driver of multiple expansion at the top of the band, not consolidation pressure (as in dermatology or GI). A buy-side platform thesis built off Pediatric Associates (TPG), USPP (Webster), Pediatrica (M33), and PM Pediatric Care (Scopia) is essentially betting on a 5-to-10 year platform formation runway, not a “consolidate-the-remaining-30 percent” thesis.

Finding 4: The 2024 pediatric residency undermatch is structural and IMG-dependent, not a one-year blip. The 2024 pediatric categorical fill rate dropped 5.3 percentage points to 91.8 percent, the worst in modern record. The 2025 recovery to 95.3 percent looks like normalization, but a structural fact remains: non-U.S. citizen IMGs filled 20.4 percent of categorical pediatric positions in 2025, up 2.0 points YoY. The pediatric workforce is increasingly IMG-dependent and increasingly fragile to immigration policy. For PE buyers, this is a real underwriting input: physician retention spend has to be modeled higher in pediatric MSO platforms than in adult primary care, and pediatric subspecialty undersupply (ID, nephrology, rheum, dev-behavioral) will not be solved by HRSA’s PSLRP at $10M per year and approximately 85-100 awards. Subspecialty MSOs will be priced for clinician scarcity from 2026 onward (HIGH).

Finding 5: Retail and virtual primary care collapsed for kids before it collapsed for adults. Walmart Health killed pediatric coverage when it killed everything April 30, 2024. CVS MinuteClinic explicitly carved pediatric primary care out of its primary care expansion (no convenience-care for kids under 5, vaccination-only for older kids) (https://www.jucm.com/cvs-accelerates-pace-of-minuteclinic-closures/) (HIGH). Walgreens VillageMD followed. The retail and virtual pullback hit pediatric care earlier and harder than adult primary care because per-visit reimbursement is lower (Medicaid mix), per-visit time is higher (well-child requires more touch), and vaccine workflow is harder to standardize. The contrarian read: the brick-and-mortar pediatric urgent care thesis is structurally stronger today than it appeared in 2022, and the closure of Brave Care (January 2025) is an idiosyncratic operator failure, not a sector signal.

Finding 6: The Welsh Carson USAP consent order is the most underpriced regulatory event in pediatric PE. The FTC’s January 7, 2025 settlement with Welsh Carson (finalized May 2025) requires 10 years of prior-notice to FTC for any acquisition or investment in anesthesia or hospital-based physician practices, including pediatric anesthesia (https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-secures-settlement-private-equity-firm-antitrust-roll-scheme-case) (HIGH). The order is the first PE-firm-as-defendant consent decree in healthcare. The pediatric MSO market has under-priced two implications: (a) hospital-based pediatric specialty PE roll-ups (neonatology, pediatric anesthesia, pediatric ED, pediatric intensivist) face a higher HSR-review bar going forward; (b) buyer concentration will rise as smaller sponsors lack the regulatory infrastructure for a 10-year reporting regime. The Welsh Carson precedent will rationalize hospital-based pediatric deal flow into 3 to 4 megacaps over the next 24 months. CT Acquisitions buyer outreach for hospital-based pediatric platforms should weight Welsh Carson, KKR, Blackstone, Apollo, and Bain disproportionately.

19b. Pediatrician density by state and the structural geographic mismatch

The American Board of Pediatrics tracks active-status pediatrician density at the state level, and the 2025 ABP data shows a structural mismatch between pediatric clinician supply and pediatric Medicaid demand that has direct implications for pediatric MSO platform geography. The Northeast (MA, CT, NY, NJ, MD) consistently sits at the high end of pediatrician density per 100,000 children, with MA above 130 per 100,000 in 2025. The Mountain West (NV, WY, ID, MT), Southeast (MS, AL, AR, GA), and rural Midwest (IA, NE, SD, ND) sit at the low end, with several states below 50 per 100,000 (HIGH directional; MEDIUM on precise state-level figures, which vary by ABP methodology revision).

The structural mismatch creates two distinct PE thesis implications. First, the high-density Northeast is where pediatric primary care MSO competition is most intense; multiple acquirers (Pediatric Associates, USPP) compete for the same bolt-on inventory in NJ and MD, which compresses multiple expansion at the regional platform level. The competitive dynamic mirrors the dental DSO and ophthalmology MSO consolidation patterns seen in CT Acquisitions’s sibling trackers. Second, the low-density Southeast and Mountain West are structurally underserved and offer the most attractive de novo pediatric MSO formation opportunity. The Pediatrica Health Group FL build-out is the cleanest demonstration of the regional density arbitrage at scale.

Florida is the single most active pediatric MSO M&A market in the United States as of June 2026. Pediatrica (M33 Growth) closed at least 5 FL pediatric primary care acquisitions in 2025, PM Pediatric Care expanded into FL via the 10-site Pediatrix Night Lite divestiture in July 2024, USPP entered the FL adjacent SE corridor via NC and SC, Pediatric Associates maintains a strong FL footprint, and TopLine MD Alliance / Femwell sits as a potential platform target with its South and Central FL multi-specialty MSO position. The concentration of FL pediatric MSO activity reflects the combination of high pediatric Medicaid population (4.5 million children covered by FL Medicaid managed care), favorable CPOM doctrine, and the proven Pediatric Associates Florida-based platform-formation playbook from 2017 to 2022.

Texas is the second most active pediatric MSO M&A market and the locus of the Imagine Pediatrics VBC SHCN model. Texas runs the STAR+PLUS, STAR Health, and STAR Kids Medicaid managed care programs, each with distinct pediatric carve-outs. The TX Medicaid pediatric pharmacy benefit transition completed in 2024, simplifying the buy-and-bill workflow for pediatric biologics including nirsevimab and palivizumab. PE platform formation in TX is currently underweighted relative to TX pediatric Medicaid population (approximately 4 million children covered).

20. Workforce: AAP shortage, residency match, BCPS pediatric pharmacy

The pediatric workforce read is the cleanest underwriting input in the pediatric MSO segment. The American Academy of Pediatrics’s projected 2,000+ pediatrician shortage for 2025 sits on top of the ABP active-status density drop from approximately 101 per 100,000 children in 2023 to approximately 82.1 per 100,000 in 2025 (HIGH on directional; MEDIUM on precise shortage figure). The 2024 categorical pediatric residency undermatch (252 unfilled positions out of 3,139 offered; 91.8 percent fill versus 97.1 percent in 2023) and the 2025 partial recovery (95.3 percent fill; 20.4 percent non-U.S. citizen IMG share) is the most material 5-year-forward pediatric MSO physician supply signal in the sector (HIGH).

The 2025 Medicine and Pediatric Specialties Match results document the bimodal pediatric subspecialty pipeline: procedural high-comp specialties (cardiology at 98.5 percent fill, GI over 95 percent, hem-onc at 97.9 percent applicant match rate) are supply-constrained on the demand side; cognitive specialties (ID, nephrology, rheum, dev-behavioral) chronically fill below 50 percent on first pass (HIGH). HRSA’s PSLRP at $100K per 3-year award and approximately 85-100 awards per fiscal year is a recruiting tool, not a supply solution (HIGH).

The Board of Pharmacy Specialties Pediatric Pharmacy certification (BCPS-Pediatric) population continues to grow, with pediatric pharmacists increasingly embedded in pediatric primary care MSOs running 340B-eligible buy-and-bill workflows for nirsevimab, palivizumab, and other pediatric biologics. The BCPS-Pediatric headcount is a leading indicator of pediatric primary care MSO sophistication on biologic margin capture (MEDIUM directional).

For PE buyers, the workforce read translates to three explicit underwriting adjustments. First, model pediatric physician retention spend at 15 to 25 percent of base compensation as a recruiting plus retention budget, materially higher than adult primary care. Second, model pediatric subspecialty fellow-recruit cost (signing bonus plus relocation plus retention plus PSLRP-eligible match) at 30 to 50 percent of first-year base, materially higher than adult subspecialty. Third, model IMG-dependent positions with explicit J-1 waiver risk under any tightening of immigration policy (the J-1 waiver Conrad 30 state-based program is the dominant pediatric IMG retention mechanism).

20b. CT Acquisitions buyer outreach playbook and sponsor-pairing matrix

The CT Acquisitions buyer outreach playbook for pediatric MSO sell-side mandates follows a four-step sponsor-pairing logic that accounts for the corrected cap-table findings in Section 3 (PM Pediatric Care), the FTC consent order regulatory drag in Section 6 (Welsh Carson / USAP), the state CPOM matrix in Section 11b, and the workforce underwriting adjustments in Section 20.

Step one: identify the seller’s natural strategic acquirer set among the active pediatric MSO PE platforms. For a sub-$5M EBITDA FL pediatric primary care practice, the natural set is Pediatrica (M33 Growth) and Pediatric Associates (TPG); both run active FL bolt-on programs. For a $2M to $5M EBITDA NJ, MD, NC, or SC pediatric primary care practice, the natural set is USPP (Webster Equity) and Pediatric Associates (TPG). For any pediatric subspecialty practice (cardiology, GI, hem-onc, neonatology) at $3M to $10M EBITDA, the natural set is Pediatrix (NYSE: MD) for neonatology and MFM and the Welsh Carson, KKR, Blackstone, Apollo, and Bain sponsor set for other subspecialties. For a pediatric urgent care platform at 5+ sites, PM Pediatric Care is the natural consolidator; at 10+ sites, sponsor-to-sponsor sale to Apollo, Bain, GTCR, Vistria, or Webster is the natural exit. For pediatric home health platforms, Aveanna (NASDAQ: AVAH) is the dominant strategic acquirer.

Step two: identify the second-tier sponsor set that may pre-empt the strategic acquirer for premium assets. For platforms at $5M+ EBITDA with credible VBC contracting capacity, the pre-emptive sponsor set includes GTCR, Webster Equity, M33 Growth, Bain Capital, J.H. Whitney, Welsh Carson Anderson & Stowe, KKR Health Care Strategic Growth, Apollo Hybrid Value, Blackstone Tactical Opportunities, Centerbridge Partners, TPG Capital, Vistria Group, and Health Evolution Partners. The 2026 sponsor screening logic should weight Welsh Carson, KKR, Blackstone, Apollo, and Bain disproportionately for any hospital-based pediatric subspecialty acquisition given the regulatory infrastructure required to operate under the post-USAP consent order regime.

Step three: structure the process to optimize for both speed and price. The 2024-2026 pediatric MSO M&A cycle saw average transaction timelines of 5 to 7 months from CT Acquisitions’s process initiation to definitive agreement, with another 3 to 6 months to close given state CPOM filings and HSR review. A bifurcated process structure (separate strategic and sponsor tracks running concurrently) is the prevailing CT Acquisitions best practice for any platform at $5M+ EBITDA.

Step four: explicitly address the regulatory and CPOM constraints in the management presentation and Q&A. The Welsh Carson USAP consent order is now table stakes for any hospital-based pediatric MSO conversation. The Oregon SB 951 / HB 3410 CPOM framework is now table stakes for any multi-state platform conversation involving West Coast geography. The California AB 3129 reintroduction trajectory is table stakes for any CA-exposed conversation. CT Acquisitions’s management presentation template now includes a dedicated regulatory readiness section that addresses each of these explicitly.

21. Seller-fit matrix

The seller-fit matrix maps pediatric MSO seller profiles to the active 2024-2026 PE platform buyer set. CT Acquisitions buyer outreach should be sequenced against this matrix.

22. Limitations and explicit gap disclosures

The following items could not be confirmed in primary sources and should be treated as open research items rather than conclusions:

• PM Pediatric Care sponsor structure. The widely-circulated “Vistria plus Apollo” framing is unverified. Crunchbase and PitchBook list Scopia, Jefferson River, Madison River, and MassLight. Treat the Vistria/Apollo claim as unverified. Verify via direct outreach to PM Pediatric Care management or via a fresh PitchBook pull before relying on for buyer outreach (MEDIUM-LOW).
• Mid-Atlantic Pediatric Affiliates and Pediatric Healthcare Alliance current ownership. Both appear as physician-owned in public LinkedIn and corporate registrations, with no announced PE transaction in 2024-2026. These groups frequently surface in pediatric M&A pipeline chatter but were not confirmable as PE-held in public record (LOW).
• TopLine MD Alliance institutional sponsor. TopLine MD’s parent Femwell Group Health is described as a privately held MSO without an identified institutional PE owner in public record. Assume physician-owned or family-office-adjacent absent contrary disclosure (MEDIUM-LOW).
• Pediatric Home Service Bain Capital growth investment. Industry reports reference a Bain Capital growth investment; precise stake size and date are not confirmed in primary sources (GAP).
• Pediatric Health Choice sale price (April 19, 2024). Pediatric Home Service acquired from Clearview; consideration not disclosed (GAP).
• Cortica Care November 2024 round investor split. $80M headline confirmed via Behavioral Health Business reporting. Full lead and participating investor list, valuation step-up, and primary versus secondary mix not in public record (MEDIUM).
• Pediatrica Health Group purchase prices. All 2025 Pediatrica acquisitions (Pinnacles, Coconut Creek, Healthy Steps, Westchester, Manatee, Scarano and Taylor) were announced without disclosed consideration (GAP on individual deal sizes).
• TeamHealth pediatric ED segment revenue. TeamHealth does not segregate pediatric ED contract revenue from broader ED staffing in public disclosures. Pediatric ED contribution is estimated, not confirmed (LOW).
• Mertz Taggart pediatric-specific quarterly multiples. Mertz Taggart’s published quarterly cadence covers behavioral health, home-based care, and post-acute; the firm does not publish a dedicated pediatric or physician services quarterly. Pediatric multiples in Section 18 are triangulated from FOCUS, Sofer, Scope, and Provident commentary (HIGH on triangulation method; not GAP).
• Public Pediatrix EV calculation. May 2026 market cap and debt figures used here are based on Q1 2026 reported balance sheet plus market quote estimates. Final calculated EV/EBITDA depends on the exact share count and debt-discount assumptions in the buyer’s model (HIGH on directional; MEDIUM on precision).
• Pediatrix segment-level economics post-divestiture. Pediatrix does not report segment-level EBITDA for the remaining neonatology, MFM, pediatric cardiology, pediatric intensivist, and OB hospitalist lines separately. The 8.2x forward multiple is a blended pure-play hospital-based pediatric subspecialty read, not a segment-specific read (MEDIUM).

23. Related CT Acquisitions research

The pediatric MSO tracker sits inside the CT Acquisitions Wave 7 healthcare tracker series. Related trackers cover adjacent or overlapping segments:

• Applied Behavior Analysis (ABA) PE roll-up tracker for the multidisciplinary autism therapy adjacency (Cortica Care comparator).
• Behavioral health (mental health and substance use) PE roll-up tracker for the integrated pediatric primary care plus behavioral health thesis (USPP / BTST).
• Ophthalmology PE roll-up tracker for the broader physician services consolidation comparator.
• Dental DSO PE roll-up tracker for pediatric dental DSO and ASC dental adjacency (Blue Cloud reference).
• Cardiology PE roll-up tracker for adult subspecialty MSO comparator.
• Oncology PE roll-up tracker for adjacent subspecialty MSO underwriting frame.
• Dialysis PE roll-up tracker for adjacent chronic-care MSO comparator.
• Urology PE roll-up tracker for adjacent subspecialty MSO comparator.
• Gastroenterology PE roll-up tracker for adjacent subspecialty MSO comparator.
• OB-GYN PE roll-up tracker for adjacent women’s health subspecialty.
• Fertility / IVF PE roll-up tracker for adjacent women’s health subspecialty.
• Healthcare PE platform map for the consolidated cross-segment buyer set.

24. Sources

• American Academy of Pediatrics, Committee on Pediatric Workforce: https://www.aap.org/en/get-involved/aap-committees/committee-on-pediatric-workforce/
• American Board of Pediatrics, Data and Workforce: https://www.abp.org/content/data-and-workforce
• NRMP Main Match Results 2025: https://www.nrmp.org/wp-content/uploads/2025/05/Main_Match_Results_and_Data_20250529_FINAL.pdf
• NRMP 2025 Match results release: https://www.nrmp.org/about/news/2025/05/nrmp-releases-2025-main-residency-match-results-and-data-report-providing-in-depth-insight-into-the-largest-residency-match-in-history/
• AAP News 2026 pediatric residency match: https://publications.aap.org/aapnews/news/34734/More-than-3-000-pediatric-residencies-filled-in
• NRMP 2025 Medicine and Pediatric Specialties Match: https://www.nrmp.org/about/news/2025/12/nrmp-celebrates-results-for-the-2025-medicine-and-pediatric-specialties-match/
• AAP News pediatric fellowship fill rate: https://publications.aap.org/aapnews/news/33913/Pediatric-fellowship-fill-rate-increases-to-78-3
• PubMed pediatric hematology-oncology match: https://pubmed.ncbi.nlm.nih.gov/40985499/
• HRSA PSLRP overview: https://bhw.hrsa.gov/funding/apply-loan-repayment/pediatric-specialty-lrp
• HRSA PSLRP FAQs: https://bhw.hrsa.gov/sites/default/files/bureau-health-workforce/funding/pediatric-specialty-lrp-faqs.pdf
• IOCDF PSLRP appropriations letter: https://iocdf.org/wp-content/uploads/2025/09/FY2026-PSLRP-Appropriations-Letter-House_FINAL.pdf
• Walmart Health closure announcement: https://corporate.walmart.com/news/2024/04/30/walmart-health-is-closing
• Sanofi Beyfortus 2025 update: https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-09-05-00-00-3095598
• Sanofi Beyfortus real-world data: https://www.news.sanofi.us/2025-07-22-BEYFORTUS-R-reduced-hospital-and-doctor-visits-for-RSV-disease-in-babies-by-87-,-according-to-largest-US-real-world-study
• GAO Medicaid unwinding report: https://files.gao.gov/reports/GAO-25-107413/index.html
• Commonwealth Fund Medicaid/CHIP renewal brief: https://www.commonwealthfund.org/publications/issue-briefs/2025/mar/how-disruptions-coverage-can-be-minimized-medicaid-chip-renewal
• KFF Medicaid and CHIP unwinding tracker: https://www.kff.org/medicaid/medicaid-and-chip-eligibility-enrollment-and-renewal-policies-as-states-resume-routine-operations-following-the-unwinding-of-the-pandemic-era-continuous-enrollment-provision/
• CMS Streamlining Rule (89 FR 22780): https://www.federalregister.gov/documents/2024/04/02/2024-06566/medicaid-program-streamlining-the-medicaid-childrens-health-insurance-program-and-basic-health
• BLS OEWS structure: https://www.bls.gov/oes/current/oes_stru.htm
• BLS OEWS occupations table: https://www.bls.gov/news.release/ocwage.t01.htm
• SHVS CHIP reauthorization summary: https://shvs.org/wp-content/uploads/2018/03/SHVS_CHIP-Reauth-Final.pdf
• CDC MMWR nirsevimab VFC pricing: https://www.cdc.gov/mmwr/volumes/74/wr/mm7437a2.htm
• Holland & Knight Oregon CPOM update: https://www.hklaw.com/en/insights/publications/2026/05/an-update-on-the-implementation-and-implications-of-oregons
• Milbank corporate backdoor to medicine: https://www.milbank.org/publications/the-corporate-backdoor-to-medicine-how-msos-are-reshaping-physician-practices/
• FTC settles with Welsh Carson on USAP: https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-secures-settlement-private-equity-firm-antitrust-roll-scheme-case
• K&L Gates Welsh Carson dismissal: https://www.klgates.com/Judge-Dismisses-FTC-Case-Against-Welsh-Carson-5-21-2024
• FTC, DOJ, HHS joint inquiry: https://www.ftc.gov/news-events/news/press-releases/2024/03/ftc-doj-hhs-launch-cross-government-public-inquiry-impact-corporate-greed-health-care
• HSGAC chairman Peters letter to Blackstone TeamHealth: https://www.hsgac.senate.gov/wp-content/uploads/2024.04.01-HSGAC-Chairman-Peters-Letter-to-Blackstone-TeamHealth.pdf
• Pediatrix strategic initiatives announcement: https://www.businesswire.com/news/home/20250113272264/en/Pediatrix-Announces-Strategic-Initiatives-For-Enhanced-Shareholder-Value-Creation
• Pediatrix Q1 2026 10-Q via Stock Titan: https://www.stocktitan.net/sec-filings/MD/10-q-pediatrix-medical-group-inc-quarterly-earnings-report-6cea3be90e86.html
• Pediatrix Inc SWOT (GuruFocus): https://www.gurufocus.com/news/8634710/decoding-pediatrix-medical-group-inc-md-a-strategic-swot-insight
• Pediatric Associates (PAFC): https://thepafc.com/
• Moody’s affirmation on Pediatric Associates via Yahoo Finance: https://finance.yahoo.com/news/pediatric-associates-holding-company-llc-152704385.html
• Pediatrica Health Group press: https://www.pediatrica.com/newsroom/press-releases/pediatrica-health-group-strengthens-commitment-to-innovative-pediatric-care-with-new-manatee-acquisition/
• Levin Associates on Pediatrica: https://healthcare.levinassociates.com/2025/06/03/pediatrica-health-group-makes-fifth-acquisition-of-2025/
• USPP Maryland entry via Aspen Pediatrics: https://www.prweb.com/releases/us-pediatric-partners-establishes-maryland-primary-care-presence-with-aspen-pediatrics-platform-partnership-302668680.html
• USPP BTST Services partnership: https://www.prweb.com/releases/us-pediatric-partners-expands-integrated-care-model-through-recent-partnership-with-btst-services-302432887.html
• Pediatric Affiliates / Physician Growth Partners: https://physiciangrowthpartners.com/transactions_post/pediatric-affiliates/
• TopLine MD Pediatrics: https://www.toplinemd.com/pediatrics/
• USACS physician buyout (March 2021): https://www.businesswire.com/news/home/20210305005550/en/US-Acute-Care-Solutions-Physician-Owners-Complete-Transaction-to-Buy-Out-Private-Equity-Partner
• Apollo Hybrid Value invests in USACS: https://ir.apollo.com/news-events/press-releases/detail/115/apollo-hybrid-value-invests-in-us-acute-care-solutions
• PM Pediatric Care 10 FL site acquisition: https://www.prnewswire.com/news-releases/pm-pediatric-care-accelerates-growth-with-acquisition-of-10-urgent-care-sites-in-florida-302203844.html
• PitchBook PM Pediatric Care profile: https://pitchbook.com/profiles/company/61436-71
• Brave Care Austin closure: https://communityimpact.com/austin/southwest-austin-dripping-springs/business/2025/01/08/bravecare-pediatric-urgent-care-permanently-closes-austin-location/
• Brave Care Portland closure: https://openminds.com/market-intelligence/bulletins/portland-oregons-brave-health-shutters-permanently/
• Aveanna closes Thrive Skilled Pediatric Care: https://ir.aveanna.com/news-releases/news-release-details/aveanna-healthcare-holdings-completes-acquisition-thrive-skilled
• Aveanna Family First Homecare announcement: https://homehealthcarenews.com/2026/03/aveannas-175-5m-acquisition-strengthens-companys-in-home-pediatric-care-play/
• Clearview Capital Pediatric Health Choice: https://www.clearviewcap.com/investment/child-health-holdings-inc-d-b-a-pediatric-health-choice/
• Great Hill Partners and Blue Cloud Pediatric Surgery Centers: https://www.greathillpartners.com/media/great-hill-partners-announces-growth-investment-in-blue-cloud-pediatric-surgery-centers
• TPG announcement on Blue Cloud sale: https://www.tpg.com/news-and-insights/great-hill-partners-announces-growth-investment-in-blue-cloud-pediatric-surgery-centers
• Imagine Pediatrics Series B: https://hitconsultant.net/2025/09/17/imagine-pediatrics-secures-67m-funding-to-expand-care-for-children-with-special-health-care-needs/
• Imagine Pediatrics PR Newswire: https://www.prnewswire.com/news-releases/imagine-pediatrics-raises-67m-to-expand-access-to-value-based-care-for-children-with-special-health-care-needs-302558856.html
• Cortica Care growth round: https://bhbusiness.com/2025/12/02/it-feels-pretty-inevitable-the-ascent-of-multidisciplinary-autism-therapy-likely-defines-industrys-future/
• Mertz Taggart Q4 2025 behavioral health: https://www.mertztaggart.com/post/q4-2025-behavioral-health-m-a-report
• FOCUS Investment Banking pediatrics valuation: https://focusbankers.com/pediatrics-practice-valuation/
• Sofer Advisors multiples guide: https://soferadvisors.com/insights/blog/medical-practice-valuation-multiples-2025-2026-complete-guide/
• PESP 2025 healthcare deals review: https://pestakeholder.org/reports/pe-healthcare-deals-2025-in-review/
• Envision Healthcare confirmation of reorganization: https://www.businesswire.com/news/home/20231011719176/en/Envision-Healthcare-Announces-Successful-Confirmation-of-Plans-of-Reorganization
• Hospitalogy Envision history: https://hospitalogy.com/articles/2023-05-11/the-rise-and-fall-of-envision-healthcare/
• Bloomberg Law on TeamHealth restructuring: https://news.bloomberglaw.com/bankruptcy-law/blackstone-backed-teamhealth-scores-1-23-billion-new-money-deal
• JUCM on CVS MinuteClinic closures: https://www.jucm.com/cvs-accelerates-pace-of-minuteclinic-closures/

25. Frequently asked questions

Related research: for every US state AG filing + notification law on healthcare PE 2024-2026 (CA SB 351 effective Jan 1 2026 NOT vetoed AB 3129; OR SB 951 NOT failed HB 4130; IN SEA 9; WA HB 2548 = first US sale-leaseback pre-notify statute; MA H 5159; Walgreens/Sycamore Aug 2025), see the 2024-2026 State AG and Legislature Healthcare PE Enforcement Tracker.

Who owns PM Pediatric Care?

Per Crunchbase and PitchBook, the confirmed institutional investors are Scopia Capital Management, Jefferson River Capital, Madison River Capital, and MassLight. The most recent disclosed round was a $50M growth raise in 2023 led by Scopia and Jefferson River. The widely-circulated “Vistria plus Apollo” framing is unverified in primary sources and should not be relied on for buyer outreach without direct sponsor confirmation (MEDIUM-LOW confidence).

When did Apollo acquire US Acute Care Solutions?

Apollo Hybrid Value’s investment in USACS closed in March 2021 (announced February 2021). Welsh Carson Anderson & Stowe fully exited as part of the same 2021 transaction. Prior CT Acquisitions memory implying a 2023 Apollo entry was incorrect.

Is the FTC case against Welsh Carson and USAP fully dismissed?

No. Judge Hanen dismissed Welsh Carson on May 13, 2024 on Section 13(b) jurisdictional grounds (no allegation Welsh Carson was currently violating the law). The case against USAP itself continued. The FTC subsequently settled separately with Welsh Carson on January 7, 2025 via a consent order requiring 10 years of prior-notice for anesthesia and hospital-based physician practice acquisitions. The FTC final order was approved in May 2025.

What is Pediatrix’s current ticker and what changed in 2024?

Pediatrix trades on the NYSE under the ticker MD. Pediatrix is the rebrand of legacy MEDNAX (January 2022). In 2024, Pediatrix completed a portfolio restructuring that divested almost all affiliated office-based practices (other than maternal-fetal medicine) plus the entire primary and urgent care service line. The divested practices contributed roughly $200M of 2023 net revenue and approximately $30M of annualized adjusted EBITDA.

Does Mertz Taggart publish a pediatric quarterly?

No. Mertz Taggart’s published cadence covers behavioral health, home-based care, and post-acute. The pediatric multiples bands in this tracker are triangulated from FOCUS Investment Banking, Sofer Advisors, Scope Research, and Provident Healthcare Partners commentary, not from a Mertz Taggart pediatric series.

How big is the projected pediatrician shortage?

The American Academy of Pediatrics projects a 2,000+ pediatrician shortage for 2025. The ABP active-status density dropped from approximately 101 per 100,000 children in 2023 to approximately 82.1 per 100,000 in 2025.

What does the Walmart Health closure mean for pediatric urgent care?

The April 30, 2024 closure of all 51 Walmart Health centers, combined with the CVS MinuteClinic pediatric carve-out (no convenience-care for children under 5; vaccination-only for older kids) and the January 2025 Brave Care wind-down, structurally strengthened brick-and-mortar dedicated pediatric urgent care platforms. PM Pediatric Care and regional rollups have absorbed displaced demand.

How many pediatric outpatient PE deals closed in 2025?

PESP tracked 9 pediatric outpatient PE investments in 2025, versus 3 in 2024, the highest growth rate (3x) of any healthcare subsector. The absolute count remains low against dermatology (50+) or eye care (40+), implying the pediatric MSO PE thesis is still in early platform-formation rather than late-cycle consolidation.

What are the typical multiples for scaled pediatric primary care MSOs?

$5M to $15M EBITDA scaled pediatric primary care platforms trade at 8.0x to 10.0x EBITDA on 1.2x to 1.7x revenue. $15M+ EBITDA platforms with credible value-based care contracting and dense geography trade at 10.0x to 12.0x EBITDA (Pediatric Associates is the reference comp).

What is the Pediatric Home Service ownership structure?

Pediatric Home Service is reported as independent / employee-owned and acquired Pediatric Health Choice from Clearview Capital in April 2024. Industry reports reference a Bain Capital growth investment in Pediatric Home Service, but the precise stake size and date are not confirmed in primary sources. We flag this as a GAP for buyer underwriting.

26. About the author

This tracker was prepared by the CT Acquisitions research desk, June 20, 2026. CT Acquisitions advises sponsor-backed and physician-owned healthcare MSOs on sell-side and buy-side M&A, with deep focus on pediatric primary care, pediatric subspecialty, pediatric home services, and adjacent value-based care. The tracker is part of CT Acquisitions’s Wave 7 healthcare PE roll-up tracker series. For buyer outreach support on any platform listed here, contact the CT Acquisitions research desk.

Last updated: June 20, 2026.